A carregar...
SGLT2 Inhibitors and Cardiovascular Outcomes: Do They Differ or There is a Class Effect? New Insights from the EMPA-REG OUTCOME trial and the CVD-REAL Study
A new group of hypoglycemic drugs has been used to treat diabetes type 2. This group is active sodium glucose co-transporter (SGLT2) or SGLT2 inhibitors. It has been shown that besides the treatment of diabetes, this drug class is responsible for the mildness of the cardiovascular events shown in pa...
Na minha lista:
| Publicado no: | Curr Cardiol Rev |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Bentham Science Publishers
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7903507/ https://ncbi.nlm.nih.gov/pubmed/31362691 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2174/1573403X15666190730094215 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|